title: Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness.
abstract: 1. Plasma concentrations of pentamidine were measured up to 1-8 months after a single 2 h i.v. infusion of 3.0 to 4.8 mg kg-1 pentamidine isethionate in 11 patients with late stage Trypanosoma gambiense sleeping sickness. 2. Maximum plasma drug concentrations varied between 713 and 2461 nmol 1-1. After termination of infusion, a rapid distribution phase over 10 min was followed by a slower distribution phase and an elimination phase prolonged over weeks to months. 3. The 'terminal' elimination rate constant could be determined in six patients and subsequent kinetic calculations showed a three to fourfold variation in plasma clearance and 'terminal' half-life (median 1126 (range 553-2036) ml min-1 and 265 (107-446) h, respectively). The median apparent volume of distribution (Vss) was 11,850 1. Renal clearance accounted for a median of 11% of total plasma clearance, indicating that metabolism is a major route of pentamidine elimination in man. 4. Side effects were few and mild and a slight or moderate decrease in blood pressure was the most common registered adverse reaction observed in four subjects. 5. The prolonged elimination of pentamidine seems inconsistent with the present recommended dosage regimen of pentamidine for treatment of trypanosomiasis of 7 to 10 parenteral doses given once daily or every second day.
authors.affiliation: Division of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden.
authors.forename: U
authors.initials: U
authors.lastname: Bronner
authors.forename: L L
authors.initials: LL
authors.lastname: Gustafsson
authors.forename: F
authors.initials: F
authors.lastname: Doua
authors.forename: O
authors.initials: O
authors.lastname: Ericsson
authors.forename: T
authors.initials: T
authors.lastname: Miézan
authors.forename: M
authors.initials: M
authors.lastname: Rais
authors.forename: L
authors.initials: L
authors.lastname: Rombo
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008549:Melarsoprol / Q000627:therapeutic use; D008657:Metabolic Clearance Rate; D010419:Pentamidine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014347:Trypanosoma brucei gambiense / Q000187:drug effects*; D014353:Trypanosomiasis, African / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D015415:Biomarkers; D010419:Pentamidine; D008549:Melarsoprol